糖尿病血管并发症患者血浆P-选择素、血浆纤溶酶原激活物抑制剂的检测

The levels of plasma P-selectin and PAI-1 in type 2 diabetes mellitus with vascular complications

目的 探讨糖尿病患者是否伴血管并发症及大、小血管并发症患者的血小板活化和内皮损伤的状态。方法 用ELISA和发色底物法 ,分别测定41例有血管并发症患者和43例无血管并发症患者的血浆P -选择素水平和血浆纤溶酶原激活物抑制剂 -1(PAI-1)活性。结果 糖尿病有血管并发症患者血浆P-选择素水平和PAI-1活性均高于无血管并发症的糖尿病患者 ;伴有大血管并发症的糖尿病患者血浆P-选择素水平高于伴微血管并发症患者 ,而PAI-1活性无差别。 结论 糖尿病血管并发症患者存在血小板活化和内皮损伤及高凝状态的病理改变。

Objective To study the plasma concentration of soluble P-selectin (sP-selectin) or plasminogen activator inhibitor-1(PAI-1) in type 2 diabetic patients with or without vascular complication. Methods We determined plasma concentration of sP-selectin and PAI-1 in 84 patients with Type 2 diabetes mellitus.The plasma sP-selectin were assayed by ELISA and plasma PAI-1 by chromogenic method.Results Plasma concentration of sP-selectin and PAI-1 in type 2 diabetic mellitus patients with vascular complications were significantly higher than those without vascular complication (P<0.01).Plasma concentration of sP-selectin in type 2 diabetic patients with macroangiopathy were significantly higher than those with microangiopathy (P<0.01).There was no difference in plasma PAI-1 between patients with microangiopathy and those with macroangiopathy (P>0.05).Conclusion These results suggest that the platelet activity and endothelial damage may contribute to the development of thrombotic complications in the diabetic state.